Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EPOPROSTENOL Cause Intentional dose omission? 10 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Intentional dose omission have been filed in association with EPOPROSTENOL (EPOPROSTENOL). This represents 0.1% of all adverse event reports for EPOPROSTENOL.

10
Reports of Intentional dose omission with EPOPROSTENOL
0.1%
of all EPOPROSTENOL reports
4
Deaths
5
Hospitalizations

How Dangerous Is Intentional dose omission From EPOPROSTENOL?

Of the 10 reports, 4 (40.0%) resulted in death, 5 (50.0%) required hospitalization.

Is Intentional dose omission Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for EPOPROSTENOL. However, 10 reports have been filed with the FAERS database.

What Other Side Effects Does EPOPROSTENOL Cause?

Dyspnoea (2,744) Headache (2,425) Diarrhoea (2,310) Nausea (2,016) Pain in jaw (1,928) Death (1,362) Flushing (1,256) Fatigue (1,133) Hospitalisation (1,078) Vomiting (1,068)

What Other Drugs Cause Intentional dose omission?

DUPILUMAB (2,269) CERTOLIZUMAB PEGOL (1,253) ADALIMUMAB (845) TOFACITINIB (845) INFLIXIMAB (815) ABALOPARATIDE (623) ETANERCEPT (615) AMBRISENTAN (595) SODIUM OXYBATE (580) CALCIUM OXYBATE\MAGNESIUM OXYBATE\POTASSIUM OXYBATE\SODIUM OXYBATE (518)

Which EPOPROSTENOL Alternatives Have Lower Intentional dose omission Risk?

EPOPROSTENOL vs EPTIFIBATIDE EPOPROSTENOL vs EPTINEZUMAB-JJMR EPOPROSTENOL vs EPTINEZUMAB\EPTINEZUMAB-JJMR EPOPROSTENOL vs EQUINE BOTULINUM NEUROTOXIN A/B/C/D/E/F/G IMMUNE FAB2 EPOPROSTENOL vs EQUINE THYMOCYTE IMMUNE GLOBULIN

Related Pages

EPOPROSTENOL Full Profile All Intentional dose omission Reports All Drugs Causing Intentional dose omission EPOPROSTENOL Demographics